Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21).
作者信息
Koo Bo Kyung
机构信息
Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
出版信息
J Obes Metab Syndr. 2021 Mar 30;30(1):72-73. doi: 10.7570/jomes20133.
Abstract
摘要
相似文献
1
Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21).信函：达格列净治疗6个月对无动脉粥样硬化性心血管疾病的肥胖2型糖尿病患者代谢谱和内皮细胞功能障碍的影响（《肥胖与代谢综合征杂志》2020年；29：215 - 21）
J Obes Metab Syndr. 2021 Mar 30;30(1):72-73. doi: 10.7570/jomes20133.
2
Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21).回应：达格列净治疗6个月对无动脉粥样硬化性心血管疾病的肥胖2型糖尿病患者代谢谱和内皮细胞功能障碍的影响（《肥胖与代谢综合征杂志》2020年；29:215 - 21）
J Obes Metab Syndr. 2021 Mar 30;30(1):74-75. doi: 10.7570/jomes21006.
3
Letter: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86).信函：甘油三酯-葡萄糖指数预测代谢不健康肥胖人群的心血管结局：一项基于全国人群的队列研究（《肥胖与代谢综合征杂志》2022年；31:178-186）
J Obes Metab Syndr. 2023 Jun 30;32(2):179-180. doi: 10.7570/jomes23017. Epub 2023 Apr 25.
4
Letter: The Differential Association between Muscle Strength and Diabetes Mellitus According to the Presence or Absence of Obesity (J Obes Metab Syndr 2019;28:46-52).信函：根据肥胖的有无探讨肌肉力量与糖尿病之间的差异关联（《肥胖与代谢综合征杂志》2019年；28:46 - 52）
J Obes Metab Syndr. 2019 Dec;28(4):295-296. doi: 10.7570/jomes.2019.28.4.295. Epub 2019 Dec 30.
5
Letter: Association of Z-Score of the Log-Transformed A Body Shape Index with Cardiovascular Disease in People Who Are Obese but Metabolically Healthy: The Korea National Health and Nutrition Examination Survey 2007-2010 (J Obes Metab Syndr 2018;27:158-65).信函：肥胖但代谢健康人群中对数转换后的A体型指数Z评分与心血管疾病的关联：韩国2007 - 2010年全国健康与营养检查调查（《肥胖与代谢综合征杂志》2018年；27:158 - 65）
J Obes Metab Syndr. 2019 Jun;28(2):139-140. doi: 10.7570/jomes.2019.28.2.139. Epub 2019 Jun 30.
6
Letter: Hepatic Fibrosis and Steatosis in Metabolic Syndrome (J Obes Metab Syndr 2022;31:61-9).信件：代谢综合征中的肝纤维化和脂肪变性（《肥胖与代谢综合征杂志》2022年；31卷：61 - 9页）
J Obes Metab Syndr. 2022 Dec 30;31(4):350-351. doi: 10.7570/jomes22049. Epub 2022 Oct 24.
7
Letter: Cut-off Values and Clinical Utility of Surrogate Markers for Insulin Resistance and Beta-Cell Function to Identify Metabolic Syndrome and Its Components among Southern Indian Adults (J Obes Metab Syndr 2020;29:281-91).信函：胰岛素抵抗和β细胞功能替代标志物的截断值及临床效用，用于识别印度南部成年人中的代谢综合征及其组分（《肥胖与代谢综合征杂志》2020年；29：281 - 91）
J Obes Metab Syndr. 2021 Dec 30;30(4):403-404. doi: 10.7570/jomes21065.
8
Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38).信函：肌肉减少症与非酒精性脂肪性肝病的存在及严重程度显著相关（《肥胖与代谢综合征杂志》2019年；28:129 - 38）
J Obes Metab Syndr. 2020 Jun 30;29(2):158-159. doi: 10.7570/jomes20018.
9
Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38).信件：肌肉减少症与非酒精性脂肪性肝病的存在及严重程度显著相关（《肥胖与代谢综合征杂志》2019年；28:129 - 138）
J Obes Metab Syndr. 2020 Mar 30;29(1):76-77. doi: 10.7570/jomes19068.
10
Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54).信函：住院患者中糖尿病与肥胖合并症与 COVID-19 不良预后相关（《肥胖与代谢综合征杂志》2021 年；30:149 - 54）
J Obes Metab Syndr. 2022 Mar 30;31(1):86-87. doi: 10.7570/jomes21094.
引用本文的文献
1
Creatinine-to-cystatin C ratio and all-cause and cardiovascular mortality in U.S. adults with nonalcoholic fatty liver disease: a nationwide cohort study.美国非酒精性脂肪性肝病成年人中肌酐与胱抑素C比值及全因死亡率和心血管死亡率：一项全国性队列研究
Front Nutr. 2025 Jun 3;12:1587757. doi: 10.3389/fnut.2025.1587757. eCollection 2025.
2
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function.格列净类药物对心血管的益处：对内皮功能的影响。
Biomedicines. 2021 Sep 29;9(10):1356. doi: 10.3390/biomedicines9101356.
本文引用的文献
1
Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.达格列净治疗6个月对无动脉粥样硬化性心血管疾病的肥胖2型糖尿病患者代谢谱和内皮细胞功能障碍的影响
J Obes Metab Syndr. 2020 Sep 30;29(3):215-221. doi: 10.7570/jomes20040.
2
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
3
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.达格列净急性改善 2 型糖尿病患者的内皮功能障碍，降低主动脉僵硬度和肾血管阻力指数：一项初步研究。
Cardiovasc Diabetol. 2017 Oct 23;16(1):138. doi: 10.1186/s12933-017-0621-8.
4
Different Relationship Between Physical Activity, Arterial Stiffness, and Metabolic Status in Obese Subjects.肥胖人群中体力活动、动脉僵硬度和代谢状态之间的不同关系。
J Phys Act Health. 2017 Sep;14(9):716-725. doi: 10.1123/jpah.2016-0595. Epub 2017 May 17.
5
Brachial-ankle pulse wave velocity and metabolic syndrome in general population: the APAC study.一般人群中的臂踝脉搏波速度与代谢综合征：亚太地区研究
BMC Cardiovasc Disord. 2016 Nov 18;16(1):228. doi: 10.1186/s12872-016-0409-x.
6
Effect of weight loss induced by energy restriction on measures of arterial compliance: A systematic review and meta-analysis.能量限制导致的体重减轻对动脉顺应性指标的影响：一项系统评价和荟萃分析。
Atherosclerosis. 2016 Apr;247:7-20. doi: 10.1016/j.atherosclerosis.2016.01.042. Epub 2016 Jan 29.
7
Effect of weight loss on pulse wave velocity: systematic review and meta-analysis.体重减轻对脉搏波速度的影响：系统评价与荟萃分析。
Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):243-52. doi: 10.1161/ATVBAHA.114.304798. Epub 2014 Nov 20.
8
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.恩格列净对无并发症的1型糖尿病患者动脉僵硬度和心率变异性的影响。
Cardiovasc Diabetol. 2014 Jan 29;13:28. doi: 10.1186/1475-2840-13-28.
9
Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial.SAVE 试验中减肥和减少胰岛素对动脉僵硬的影响。
Cardiovasc Diabetol. 2012 Sep 22;11:114. doi: 10.1186/1475-2840-11-114.
10
Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms.超重和肥胖的年轻成年人中，体重减轻可降低动脉僵硬度：潜在机制。
Atherosclerosis. 2012 Aug;223(2):485-90. doi: 10.1016/j.atherosclerosis.2012.05.022. Epub 2012 May 30.
Zotero 插件